Tuberculosis is a serious threat to public health throughout the world. A series of new 13-n-nonylprotoberberine derivatives was designed, synthesized and evaluated for antimycobacterial activity against Mycobacterium tuberculosis strain H 37 Rv. Several compounds (2, 11a-c, 11g, 13d, 15c) exhibited excellent anti-tubercular activity with an MIC below 1.0 mg/mL. Notably, compound 13d showed potential antibacterial effect against both drug-susceptible and multidrug-resistant (MDR) M. tuberculosis with MIC ranges of 0.0625-1.0 mg/mL. These results suggest a mode of action different from that of the current anti-mycobacterial drugs rifampicin and isoniazid. Hence, compound 13d is an attractive lead compound for the development of new antitubercular agents.
Introduction
Tuberculosis (TB), which was once considered eradicated, has again become a major global health concern. Over the past decade, at least 30 million individuals have died of TB infection and approximately one-third of the world's population has been infected with latent or persistent Mycobacterium tuberculosis (M. tuberculosis). Moreover, more than 8 million people develop active TB every year globally, and if the trend continues there will be a total of 36 million disease-related deaths by the year 2020 [1] [2] [3] .
The emergence of new multidrug-resistant tuberculosis (MDR-TB) strains has further complicated the management of this disease. An outbreak of recently recognized ''extensively drug-resistant tuberculosis'' (XDR-TB) threatens global TB control. A 100% correlation has been observed in XDR-TB with HIV co-infection and mortality [4] [5] [6] [7] . The difficulty in managing TB is the prolonged treatment duration and the emergence of drug resistance and co-infection with HIV/AIDS. However, no new chemical scaffold for the treatment of this disease has been approved in the past 40 years [8] [9] [10] . There is an urgent need to discover new classes of molecules that will not be affected by cross-resistance to current anti-mycobacterial drugs 11 .
In an attempt to discover novel antitubercular agents, we recently identified 13-n-octylprotoberberine (1) as promising and the corresponding SAR revealed that the n-octyl at the 13-position significantly improved the anti-mycobacterial activity against M. tuberculosis 12 . In continuation of our efforts to identify new anti-TB agents, we turned our attention to chemical modifications of the longer linear alkyl side-chains (m48) at the 13-position of berberine (BBR, Fig. 1 ). On the basis of this strategy, compounds 2 (13-n-nonyl), 3 (13-n-decyl) and 4 (13-n-undecyl) were synthesized and evaluated for their activity (Fig. 1) . The results showed that compound 2, bearing a n-nonyl at the 13-position, exhibited the most potent activity against TB among the BBR analogs possessing different linear alkyl side-chains at the 13-position (m¼0-11) . Therefore, in the present study a series of new 13-nonylprotoberberine analogs was designed, synthesized and evaluated for their anti-mycobacterial activity against both drug-susceptible and drug-resistant M. tuberculosis strains isolated from the patients with tuberculosis infections.
Results and discussion

Synthetic routes
Twenty target compounds were synthesized using BBR, 5 or 6 13 as the starting materials as described in Scheme 1.
These compounds were selectively reduced to the corresponding dihydroprotoberberines 7a-c with NaBH 4 in the presence of K 2 CO 3 /NaOH 14 . Intermediates 7a-c were then mixed with various aldehydes in an ethanol/acetic acid (8/2) mixture at 85À95 1C for 5 h, followed by acidification with HCl (2 M) to provide 13-alkylprotoberberine analogs 2-4 and 8-9 (Route A) in total yields of 15À36% 14, 15 .
In Route B, intermediate 10 was prepared by a decomposition reaction of compound 2 at 195À210 1C under vacuum (30À40 mm Hg) for 30 min followed by recrystallization in ethanol/concentrated HCl (95/5, v/v) in an 89% yield 16 . Final products 11a-f were obtained by an esterification reaction of 10 with acyl chloride using pyridine as the base in acetonitrile at reflux temperature in yields of 25À48% 17, 18 , while 11g was obtained through an alkylation reaction of 10 with alkyl halide using K 2 CO 3 /KOH as the base in DMF at 60À80 1C, with yields of 26% 19, 20 .
Compound 2 was treated with phloroglucinol in H 2 SO 4 (60%) at 90À95 1C to afford the key intermediate 12 in an 82% yield 21 , which was then put through an alkylation reaction with an alkyl halide to afford target compounds 13a-d in total yields of 5À24% 19, 20 (Route C). Target compounds 15a-c were obtained by mixing compound 2 with AlCl 3 in CH 2 Cl 2 to afford intermediate 14 [22] [23] [24] followed by an alkylation reaction with alkyl halide in total yields of 23-32% 19, 20 (Route D). All desired products were purified by flash chromatography using CH 2 Cl 2 /CH 3 OH as the gradient eluent.
SAR analysis for anti-mycobacterial activity
All the synthesized derivatives were first evaluated for their activity against the multiplication of wild-type M. tuberculosis strain H 37 Rv by the microplate alamar blue assay (MABA). Rifampicin (RIF) and isoniazid (INH) were used as reference drugs. The structures of 20 new 13-n-nonylprotoberberine derivatives and their anti-mycobacterial activities against M. tuberculosis H 37 Rv are shown in Table 1 .
We first concentrated SAR analysis on the variation of the substituents on the D ring. When the methoxy group was transferred from the 9-position to the 11-position, the resultant 8 showed decreased anti-mycobacterial activity with an MIC of 2.0 mg/mL as compared to compound 2. Replacement of the 9-methoxy with a hydrogen, hydroxyl, acetyloxy, propionyloxy, butyryloxy, hexanoyloxy, octanoyloxy, decanoyloxy or propoxy, generated nine new compounds (9, 10, 11a-g) for testing. The results showed that compounds 11a-b Figure 1 The chemical structures and anti-mycobacterial activities of compounds BBR and 1-4 (1: m¼ 8, MIC: 2.0 mg/mL; 2: m¼ 9, MIC: 0.848 mg/mL; 3: m¼10, MIC: 4.0 mg/mL; 4: m¼11, MIC: 1.0 mg/mL). and 11g exhibited a remarkable MIC of 0.125 mg/mL against M. tubercolusis H 37 Rv, much greater than that of the lead compound 2. The results indicated that introduction of a suitable substituent at the 9-position, such as acetyloxy, propionyloxy or propoxy, might be helpful for the antimycobacterial activity.
Next, SAR was carried out to explore at the 2-and 3positions on the A ring. When the oxacyclopentene was opened, the resultant compound 12 showed potent activity against TB at an MIC of 0.5 mg/mL, slightly higher than that of its parent 2. Introducing a methoxy, ethoxy or ethylenedioxy at 2-and/or 3-position (13a-d) displayed similar activities with MIC values between 0.25 and 0.5 mg/mL. In another variation, further modifications were carried out at the 2-, 3-and 9-positions. The substituents, including a hydroxyl, ethoxyl or ethylenedioxy, were introduced to some or all of these positions. Among the four new analogs (14, 15a-c), compound 15c, possessing 2,3,9-triethoxy exhibited the strongest anti-tubercular activity with an MIC of 0.0625 mg/mL. We deduced that introduction of a side-chain at the 2-and/or 3-position(s), especially ethoxy, might significantly enhance the anti-mycobacterial activity against M. tuberculosis.
Anti-resistant TB effect of the key compounds
Among the newly synthesized compounds, most of them exhibited promising activities against the wild-type strain H 37 Rv with MIC ranges of 0.0625À2.0 mg/mL. Although compound 15c afforded the most potent effect against M. tuberculosis, it showed a metabolic instability in vivo (data not shown). We consider that di-ethoxy at the 2-and 3-positions might form a blockage that reduces the stability of compound 15c, and subsequently be metabolized easily in vivo. Therefore, compounds 2, 11a, 11c and 13d possessing various substituents at 2-, 3-, and 9-positions were selected for evaluation of their anti-mycobacterial activity against MDR strains of M. tuberculosis. As described in Table 2 , RIF and INH showed a partial decrease or complete loss in activity against MDR stains 44, 83, 164, 431 and 926, isolated from patients with tuberculosis in China. Compounds 11a and 11c showed the moderate inhibition activities, while compound 13d displayed the most potent anti-mycobacterial effect with MIC values of 0.0625-0.5 mg/mL, suggesting a different mode of action from RIF and INH. The results revealed that compound 13d represents an attractive lead compound for the development of new anti-TB agents.
Conclusions
In conclusion, a novel class of 13-n-nonylberberine derivatives with promising antitubercular activity was identified. SAR analysis revealed that a 13-n-nonyl side-chain might play an important role in anti-mycobacterial activities against M. tuberculosis strains. Among these analogs, the newly synthesized compound 13d exhibited an excellent effect toward both drug-susceptible and drug-resistant strains of M. tuberculosis, indicating a different mode of action from the marketed anti-mycobacterial drugs RIF and INH. Elucidation of the mode of action of 13d is one of the goals of the ongoing research program in our laboratories.
Experimental
Chemistry
Melting point (mp) was obtained with CXM-300 melting point apparatus and uncorrected. The 1 H NMR spectra was performed on a Varian Inova 400 MHz spectrometer (Varian, San Francisco, CA) and 13 C NMR on a Bruker Avance III 400 spectrometer in CD 3 OD or (CD 3 ) 2 SO, with Me 4 Si as the internal standard. ESI high-resolution mass spectra (HRMS) were recorded on an Autospec UItima-TOF mass spectrometer (Micromass UK Ltd, Manchester, UK). Flash chromatography was performed on CombiflashRf 200 (Teledyne, Nebraska, USA), particle size 0.038 mm.
4.2.
General procedure for the synthesis of compounds 2-4 and 8-9 (Procedure A) 4.2.1. 2,3-Methylenedioxy-9,10-dimethoxy-13-nnonylprotoberberine chloride (2) To a stirred solution of BBR (7.43 g, 20 mmol) and K 2 CO 3 (8.30 g, 60 mmol) in methanol (250 mL), 5% NaOH (10 mL) solution containing NaBH 4 (0.80 g, 21 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 2 h and the precipitated product was filtered, washed with water (20 mL) and 30% ethanol (20 mL), and then recrystallized from absolute ethanol to provide 7a as a dark green solid.
To a stirred solution of 7a (7.0 g, 20.2 mmol) in 80% ethanol (200 mL), nonylaldehyde (10 mL) and acetic acid (50 mL) were added. The reaction mixture was heated at 85À95 1C for 5 h. The crude reaction was then concentrated, and the red oily residue was suspended in diethyl ether (200 mL) and stirred at room temperature for 2 h. After filtration, the diethyl ether layer was collected and concentrated, and the residue was acidified by 2% HCl (100 mL), and stirred at room temperature for 0.5 h. The solid was obtained by filtration to afford the title compound 2 (3.57 g, 36%) as a yellow powder. Mp 162À164 1C; 1 H NMR (CD 3 OD): d 0.84 
2,3-Methylenedioxy-9-acetyloxy-10-methoxy-13-nnonylprotoberberine chloride (11a)
To a solution of CH 3 CN (5 mL) was added 10 (200 mg, 0.41 mmol) at room temperature and heated to form a darkred solution, to which was then added anhydrous pyridine (0.036 mL) and acetyl chloride (0.143 mL, 2.0 mmol). The resulting mixture was refluxed at 75À80 1C for 6À8 h. The solvent was removed by evaporation, the crude product was purified by flash chromatography over silica gel using CH 2 Cl 2 / CH 3 OH (95/5) as the gradient eluent, affording compound 11a (82 mg, 38%) as a yellow powder. Mp 98À100 1C; 1 (12) To a stirred solution of 60% H 2 SO 4 (60 mL), phloroglucin (1.69 g, 10.39 mmol) was added portion-wise to form a colorless solution, after which compound 2 (1.50 g, 3.01 mmol) was added portion-wise and the mixture was stirred at 90À95 1C for 10À15 min. The mixture was then poured into saturated brine (30 mL) immediately with rapid stirring, and the resulting mixture was stirred at room temperature for 2 h and cooled allowing precipitation. After filtration and a water wash the filter cake layer was adjusted to neutral with NaOH (1 M), then adjusted to acidity with HCl (2 M), stirred, filtered to collect the precipitate, followed by recrystallization with ethanol/concentrated HCl (95/5) to afford compound 12 (1.2 g, 82%) as a dark red powder. Mp 118À120 1C; 1 H NMR (CD 3 OD) 
Biological activity assay
All synthesized compounds were measured for their anti-TB activities against the multiplication of drug-susceptible or drug-resistant M. tuberculosis strains with MABA at different concentration with RIF and INH as positive controls. Subsequent two-fold dilutions were performed in 100 mL of 7H9 media in the 48-well microplates, and then 100 mL of bacterial suspension was added to the wells. The amount of bacteria in each well was 4 Â 10 À4 mg/mL. Plates were incubated at 37 1C. At the optimal time, alamar blue solution was added to the plate. Results were recorded at 24 h post-reagent addition. Visual MIC was defined as the lowest concentration of drug that prevented a color change.
